Korean Companies Step Up Development Of Enbrel Biosimilars As Amgen Ramps Up Its Pipeline
This article was originally published in PharmAsia News
After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.
You may also be interested in...
The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
LG Life Obtains Korea FDA Approval To Conduct Clinical Trials For Biosimilar Following Celltrion, Hanwha
SEOUL - South Korea's LG Life Sciences became the third local pharma company to obtain Korea FDA approval to conduct clinical trials of its biosimilar, code-named LBEC0101, on the heels of clinical trial clearance for Celltrion and Hanwha Chemicals